Probiotics in human immunodeficiency virus infection

A systematic review and evidence synthesis of benefits and risks

George M. Carter, Aryan Esmaeili, Hardikkumar Shah, Debbie Indyk, Matthew Johnson, Michael Andreae, Henry S. Sacks

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.

Original languageEnglish (US)
Article numberofw164
JournalOpen Forum Infectious Diseases
Volume3
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Probiotics
Virus Diseases
Sepsis
HIV
Fungemia
Bacterial Vaginosis
Bayes Theorem
CD4 Lymphocyte Count
Dietary Supplements
Bacteremia
Practice Guidelines
Meta-Analysis
Diarrhea
Randomized Controlled Trials
Recurrence
Population

Keywords

  • Bacteremia
  • Fungemia
  • HIV infection
  • Probiotics

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Probiotics in human immunodeficiency virus infection : A systematic review and evidence synthesis of benefits and risks. / Carter, George M.; Esmaeili, Aryan; Shah, Hardikkumar; Indyk, Debbie; Johnson, Matthew; Andreae, Michael; Sacks, Henry S.

In: Open Forum Infectious Diseases, Vol. 3, No. 4, ofw164, 2016.

Research output: Contribution to journalReview article

Carter, George M. ; Esmaeili, Aryan ; Shah, Hardikkumar ; Indyk, Debbie ; Johnson, Matthew ; Andreae, Michael ; Sacks, Henry S. / Probiotics in human immunodeficiency virus infection : A systematic review and evidence synthesis of benefits and risks. In: Open Forum Infectious Diseases. 2016 ; Vol. 3, No. 4.
@article{cb5582188df84500aac9d48bf8f624a0,
title = "Probiotics in human immunodeficiency virus infection: A systematic review and evidence synthesis of benefits and risks",
abstract = "People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95{\%} credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.",
keywords = "Bacteremia, Fungemia, HIV infection, Probiotics",
author = "Carter, {George M.} and Aryan Esmaeili and Hardikkumar Shah and Debbie Indyk and Matthew Johnson and Michael Andreae and Sacks, {Henry S.}",
year = "2016",
doi = "10.1093/ofid/ofw164",
language = "English (US)",
volume = "3",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Probiotics in human immunodeficiency virus infection

T2 - A systematic review and evidence synthesis of benefits and risks

AU - Carter, George M.

AU - Esmaeili, Aryan

AU - Shah, Hardikkumar

AU - Indyk, Debbie

AU - Johnson, Matthew

AU - Andreae, Michael

AU - Sacks, Henry S.

PY - 2016

Y1 - 2016

N2 - People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.

AB - People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.

KW - Bacteremia

KW - Fungemia

KW - HIV infection

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=84996538572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996538572&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofw164

DO - 10.1093/ofid/ofw164

M3 - Review article

VL - 3

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 4

M1 - ofw164

ER -